Biogen (BIIB) Reports Topline Phase 3 Results of Tofersen and its Open-Label Extension in SOD1-ALS
Go back to Biogen (BIIB) Reports Topline Phase 3 Results of Tofersen and its Open-Label Extension in SOD1-ALS| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 229.02 +1.42 (0.62%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $227.60 | 52 Week High | $333.65 | |||
| Open | $225.87 | 52 Week Low | $223.02 | |||
| Day High | $230.49 | P/E | 29.32 | |||
| Day Low | $225.51 | EPS | $7.81 | |||
| Volume | 490,791 | |||||
